KOVALTRY®
GIVE HIM THE OPPORTUNITY
TO EXPLORE THE POSSIBILITIES
The only unmodified, full length rFVIII offering the potential
for as few as 2 infusions per week1*
INDICATIONS
KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived,
full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:
On-demand treatment and control of bleeding episodes
Perioperative management of bleeding
Routine prophylaxis to reduce the frequency of bleeding episodes
KOVALTRY® is not indicated for the treatment of von Willebrand disease.
SELECTED IMPORTANT SAFETY INFORMATION
KOVALTRY® is contraindicated in patients who have a history
of hypersensitivity reactions to the active substance, to any
of the excipients, or to mouse or hamster proteins.
Please see additional Selected Important Safety Information
on following pages. For additional important risk and use
information, please see Brief Summary on following pages.
*Compared to other rFVIII products.